Continuous Peripheral Nerve Blocks for Phantom Limb Pain

Not currently recruiting at 7 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: University of California, San Diego
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a treatment to manage phantom limb pain, the sensation of pain in an amputated limb. The method under investigation is continuous peripheral nerve blocks (CPNB), which uses numbing medicine to block pain signals from reaching the brain and potentially reduce opioid use. Participants will receive either a standard or experimental dose to determine which is more effective in improving post-amputation recovery. The study seeks participants scheduled for a lower limb amputation who are willing to use this pain management method for seven days after surgery. As a Phase 4 trial, it involves an FDA-approved treatment and aims to understand how it can benefit more patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What is the safety track record for continuous peripheral nerve blocks?

Previous studies have shown that continuous peripheral nerve blocks (CPNB) are safe and well-tolerated. These studies found that CPNB significantly reduces phantom limb pain and improves both physical and emotional health for at least a month after treatment. No major side effects affected the whole body, indicating the treatment only impacts the area around the nerve.

Patients experienced less pain with CPNB, and it more than doubled the chance of a noticeable reduction in pain. This evidence suggests that the treatment is generally safe for those dealing with phantom limb pain after an amputation.12345

Why are researchers enthusiastic about this study treatment?

Researchers are excited about the continuous peripheral nerve blocks for phantom limb pain because they offer a targeted approach to pain management. Unlike traditional treatments like oral painkillers or antidepressants, these nerve blocks use bupivacaine or ropivacaine, which are administered directly through perineural catheters to numb the affected area. The experimental treatment uses a higher concentration of these anesthetics over a full seven days, potentially providing more sustained relief. This method could offer quicker and more effective pain reduction, improving the quality of life for those suffering from phantom limb pain.

What evidence suggests that continuous peripheral nerve blocks are effective for phantom limb pain?

Research has shown that continuous peripheral nerve blocks (CPNB) can greatly reduce phantom limb pain. In this trial, participants will join different treatment arms to evaluate CPNB's effectiveness. One arm will receive a control infusion of Bupivacaine 0.1% or Ropivacaine 0.2% for one day, followed by normal saline. The other arm will receive an experimental infusion of Bupivacaine 0.3% or Ropivacaine 0.5% for seven days. Previous studies found that using CPNB for six days helped lessen both physical and emotional problems for at least a month. Another study revealed that this treatment more than doubled the chances of significant pain relief for those with phantom limb pain. Some patients even experienced complete pain relief soon after the nerve block, with effects lasting up to seven months. These findings suggest that CPNB is a promising way to manage phantom limb pain after amputation.12346

Who Is on the Research Team?

Brian M. Ilfeld, MD - Anesthesiology ...

Brian Ilfeld, MD

Principal Investigator

University California San Diego

Are You a Good Fit for This Trial?

This trial is for individuals scheduled for unilateral lower limb amputation who are willing to have a nerve block infusion for 7 days, including after hospital discharge. They must not have liver or kidney issues, allergies to study meds, be pregnant or incarcerated, and must be able to communicate with researchers.

Inclusion Criteria

I am scheduled for a leg amputation below the hip that includes part of my foot.
I am willing to undergo a 7-day perineural infusion treatment.
I am scheduled for pain relief via nerve blocks around surgery time.
See 1 more

Exclusion Criteria

I have liver or kidney problems.
Allergy to any study medication
Pregnancy
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive continuous peripheral nerve blocks (CPNB) with either bupivacaine or ropivacaine for pain management post-amputation

7 days
Daily monitoring via telephone

Follow-up

Participants are monitored for mobility, pain, and opioid consumption at various intervals post-surgery

12 months
Postoperative days 1, 2, 8; Months 1, 3, 6, 9, and 12

What Are the Treatments Tested in This Trial?

Interventions

  • Control continuous peripheral nerve blocks
  • Experimental continuous peripheral nerve blocks
Trial Overview The study tests if using a high-concentration continuous peripheral nerve block (CPNB) around the time of leg amputation can improve recovery by reducing phantom limb pain and opioid use. Participants will either receive the experimental CPNB or a control version in this randomized, triple-masked trial.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Group II: ControlExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, San Diego

Lead Sponsor

Trials
1,215
Recruited
1,593,000+

Wake Forest University Health Sciences

Collaborator

Trials
1,432
Recruited
2,506,000+

Massachusetts General Hospital

Collaborator

Trials
3,066
Recruited
13,430,000+

The Cleveland Clinic

Collaborator

Trials
1,072
Recruited
1,377,000+

Johns Hopkins University

Collaborator

Trials
2,366
Recruited
15,160,000+

Boston VA

Collaborator

Trials
1
Recruited
200+

Mass. General Hospital

Collaborator

Trials
1
Recruited
200+

Brigham and Women's Hospital

Collaborator

Trials
1,694
Recruited
14,790,000+

United States Department of Defense

Collaborator

Trials
940
Recruited
339,000+

United States Naval Medical Center, San Diego

Collaborator

Trials
110
Recruited
24,200+

Citations

Ambulatory continuous peripheral nerve blocks to treat ...We conclude that a 6-day continuous peripheral nerve block reduces phantom limb pain as well as physical and emotional dysfunction for at least 1 month. 1.
Patient-centered results from a multicenter study of continuous ...Among patients with postamputation phantom pain, a continuous peripheral nerve block more than doubles the chance of a clinically relevant improvement in pain ...
Study Details | NCT03461120 | Improving Postamputation ...Hypotheses 4 & 5: Phantom and residual limb pain will be significantly decreased within the 12 months following a surgical amputation with a 7-day high- ...
Ambulatory continuous peripheral nerve blocks to treat...We conclude that a 6-day continuous peripheral nerve block reduces phantom limb pain as well as physical and emotional dysfunction for at least 1 month.
Continuous blockade of both brachial plexus with ...Within 20 min of catheter placement complete pain relief was achieved. The patient did not need any other analgesics and remained painfree for 7 months. Neither ...
Continuous Peripheral Nerve Block With Ropivacaine ...Patients with postamputation phantom pain can experience improvement in pain intensity with a continuous peripheral nerve block.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security